Oxlumo
Oct 09, 2023
Can Novo’s Rivfloza Outperform Its Rival Alnylam’s Oxlumo in Primary Hyperoxaluria Treatment Space?
In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a trea...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
